Core Insights - The article discusses the challenges in cell therapy, highlighting the issues of cell delivery, survival, and functionality, which are critical for effective tissue repair and treatment of degenerative diseases [1][5][7] - A breakthrough research from a collaborative team introduces a magnetic soft robotic system that not only delivers cells to targeted areas but also provides mechanical stimulation to enhance cell function [2][4] Group 1: Challenges in Cell Therapy - Traditional methods of cell injection face significant limitations, including poor targeting, low survival rates, and loss of function after cells are detached from their physiological environment [5][6][7] - The demand for high cell quantities in clinical treatments (1 × 10⁶ to 2.5 × 10⁶ cells per square centimeter) is not met by existing magnetic micro-robots, which often serve only as passive carriers [7] Group 2: Innovative Robotic Solution - The newly developed magnetic soft robotic system integrates in-situ mechanical stimulation with targeted cell delivery, inspired by the muscle training process [8][9] - The robot is made from a soft silicone elastomer embedded with magnetic particles, allowing it to be controlled wirelessly through external magnetic fields [9][10] Group 3: Mechanism and Functionality - The robot's porous structure facilitates cell adhesion and growth, while its magnetic drive allows for precise movement and mechanical training of the cells [10][11] - Experimental results show that cells delivered by the robot exhibit over 85% survival rates and enhanced proliferation when subjected to mechanical stimulation [14] Group 4: Enhanced Cell Performance - Mechanical stimulation significantly improves muscle cell functionality, leading to better alignment and stronger contractions compared to unstimulated cells [16][18] - The robot's design allows for the creation of 3D cell-laden hydrogels, which also show improved cell orientation and tissue engineering potential after mechanical training [24] Group 5: Delivery and Navigation - The integrated robotic platform combines magnetic driving with ultrasound imaging for real-time navigation and control, demonstrating effective delivery through narrow bile ducts in a pig liver model [26][28] - The robot can adapt to varying pipe sizes and effectively deliver cells, achieving a survival rate of over 95% post-delivery [32] Group 6: Biocompatibility and Future Challenges - Initial biocompatibility tests in rats show no significant inflammation or necrosis, indicating the potential for safe medical applications [34] - Future challenges include developing biodegradable materials, exploring more complex stimulation patterns, and conducting in vivo validations to ensure long-term safety and efficacy [36][38]

撰文丨王聪 编辑丨王多鱼 排版丨水成文 3D 生物打印 是一种三维生物制造技术，用于精确地排列细胞和含细胞生物材料 （生物墨水） ，以构建具有所需功能的立体生物组织。通常，生物墨水依靠水凝 胶基质在生物打印之前、期间或之后稳定并交联构建体。尽管此类方法推进了仿生学的发展，但其难以实现体内细胞的高密度，且大量水凝胶成分可能会阻碍细 胞间相互作用，导致表型丧失并降低组织功能。 近年来，无支架的 3D 生物打印技术被提出以解决细胞密度问题，但这类方法通常依赖于挤出式生物打印，难以无法达到复杂组织所需的分辨率和复杂度。 2025 年 12 月 8 日， 哈佛医学院 张宇 教授团队在国际大奖学术期刊 Cell 上发表了题为： Biomaterial-minimalistic photoactivated bioprinting of cell- dense tissues 的研究论文。 王冕 （现为同济大学研究员） 、 李婉露 （现为 上海交通大学 助理教授） 、 郝晋 （现为上海交通大学助理研究员） 、 蔡玲 为 论文共同第一作者 。 该研究开发了一种去材料化、无支架的 高细胞密度生物墨水 （ Cell-dense ...

Summary of Zhenghai Biological Conference Call Company Overview - **Company**: Zhenghai Biological - **Industry**: Biopharmaceuticals, specifically focusing on bone repair materials and dental products Key Points and Arguments Financial Performance - **Net Profit Decline**: Net profit decreased by 45.34% year-on-year, primarily due to tax policy adjustments (VAT increased from 3% to 13%) and intensified market competition, particularly in the meninges product segment and oral implant sector [2][4][5] - **Revenue Trends**: For the first three quarters of 2025, total revenue was 276 million yuan, a decrease of 5.36% year-on-year. In Q3 alone, revenue was 87.87 million yuan, down approximately 5% year-on-year [3][4] - **Gross Margin**: The overall gross margin was around 85%, showing a recovery compared to the first half of the year due to changes in product mix [3] Product Performance - **Active Biological Bone Products**: Currently in 196 hospitals, with expectations for significant revenue growth due to the inclusion of BMP-2, which enhances bone induction. The company aims to increase market share by expanding hospital admissions and improving penetration in benchmark hospitals [2][6][11] - **Stem Cell Project**: In the process of technology validation, this project is crucial for addressing clinical tissue repair and regeneration issues, indicating strategic importance [7] - **Oral Membrane Products**: The second-generation oral repair membrane is in the early promotion stage, contributing minimally to revenue. The company is focusing on applications in soft tissue defects and avoiding price wars [2][8][10] Market Dynamics - **Market Competition**: The oral implant market is facing challenges due to price governance and a sluggish consumer market, leading to a decline in private institution implant volumes. Some patients are opting for repair treatments instead of implants, impacting the growth of bone powder and membranes [2][13] - **Price Pressure**: The company is experiencing price declines across its products, although it maintains a stable gross margin. Sales and management expenses have increased, putting pressure on net profits [5][16] Regulatory and Development Updates - **Regulatory Approvals**: The company is tracking the procurement policies for artificial bone repair materials and is preparing for the registration of new products like the calcium silicate bone powder, expected to receive certification by the end of this year or early next year [4][20] - **Future Product Launches**: The company anticipates launching the intrauterine repair membrane in 2026 and the breast patch in 2027, with detailed market strategies to be developed closer to launch dates [17] Strategic Outlook - **Acquisition Plans**: The company is open to acquisitions to expand its business pipeline and explore new growth opportunities [29] - **International Expansion**: Zhenghai Biological is exploring overseas business opportunities and has begun preparations for international certifications [28] - **Employee Incentives**: The company has completed share buybacks for employee incentives and plans to implement stock incentive schemes based on future performance [30] Future Market Perspective - **Confidence in Growth**: The company remains optimistic about future development, focusing on core business growth, new product launches, and cost control to achieve good performance returns [31]

Core Viewpoint - The article discusses a groundbreaking technology called "liquid droplet printing," developed by a team led by researcher Song Yanlin at the Chinese Academy of Sciences, which allows for the precise attachment of ultra-thin electronic membranes to complex biological surfaces using a droplet of water as a medium [1][2]. Group 1: Technology Overview - The "liquid droplet printing" technology enables the attachment of flexible electronic devices to irregular surfaces such as human skin, nerves, and the brain without damaging the delicate membranes [2][3]. - The process utilizes a droplet of water to pick up the ultra-thin membrane and release it onto the target surface, acting as both a facilitator for adhesion and a lubricant to prevent stress-related damage during application [2][5]. Group 2: Experimental Results - Experiments demonstrated that even a gold film with a thickness of only 150 nanometers could be successfully attached to complex structures like paramecium, dandelion fluff, and shell textures using this technology [5]. - In live experiments, silicon-based electronic membranes were printed onto the sciatic nerve and cerebral cortex of mice, achieving a non-destructive and conformal attachment that allowed for the conversion of light signals into electrical signals, successfully stimulating nerve activity [5]. Group 3: Future Prospects - This technology breaks the limitations of traditional flexible electronic device attachment and has broad application potential in fields such as brain-machine interfaces, neural regulation, and wearable devices, with possible extensions to tissue engineering and smart displays [6]. - The innovation is likened to the impact of printing technology on human civilization, suggesting that "liquid droplet printing" could revolutionize the preparation and attachment of electronic devices, making it as easy as applying a screen protector [6].

Industry Overview - Regenerative medicine (RM) utilizes biological and engineering theories to promote self-repair and regeneration of the body, or to construct new tissues and organs for repairing, regenerating, and replacing damaged tissues and organs [1][4] - The global regenerative medicine market is expanding, with the market size projected to grow from $20.04 billion in 2021 to $35.82 billion in 2024 [1][12] Market Status - Regenerative medicine is considered the "third medical revolution" following drug and surgical treatments, becoming a core component of life science strategies globally [6][12] - The industry includes upstream raw materials and equipment supply, midstream product R&D and production, and downstream application through medical institutions and aesthetic organizations [4][12] Policy and Regulatory Environment - Various countries have implemented policies to promote the development of regenerative medicine, such as the U.S. "21st Century Cures Act" and the EU's regulations on biotechnology [7][9] - In China, policies have been established to support the clinical application of regenerative medicine technologies, including the management of stem cell therapies and the promotion of innovative medical technologies [9][23] Market Competition - The regenerative medicine sector has attracted numerous companies, with major players including Johnson & Johnson, Bard, Geistlich, and domestic firms like Zhenghai Biological, Guanhou Biological, and Maipu Medical [16][18] - The market is characterized by a diverse range of products and applications, with companies focusing on specific therapeutic areas such as cancer treatment, tissue repair, and organ transplantation [18][20] Development Trends - The industry is witnessing technological integration and innovation, with advancements in 3D bioprinting, gene editing, and artificial intelligence enhancing treatment efficacy [22][24] - The dual drive of policy support and capital investment is accelerating the commercialization of regenerative medicine, with increasing coverage of medical insurance for regenerative products [23][24]

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 展位有限 报名：首届全球心血管大会 | 奖项评选 报名：首届全球骨科大会 | 奖项评选 随着全球科技的不断进步，医疗器械创新的步伐也在加快。根据美国的统计数据， 70%的医疗器械创新想法 都来自于临床医生的实际经验和需求 。临床医 生不仅是治疗的执行者，也是医疗器械创新的重要推动者。 过去，许多一线城市的三甲医院的大专家们已经走在了创新的前沿，取得了显著的成果转化。而在更为广泛的地区，比如像东北地区，医工交叉仍然处于一 个萌芽阶段，充满了探索的机会与挑战。 亓明教授，作为大连医科大学附属第一医院血管外科的资深专家，正是这种医工交叉领域探索的代表之一 。思宇 MedTech记者近日专访了亓教授，探讨了他在这一领域的深刻思考与实践。 在血管外科工作超过20年的亓明教授，近年来开始逐渐对医工交叉领域产生了浓厚兴趣。对于他来说，这一转变并非偶然，而是基于长期的临床积累以及对 创新医疗器械需求的深刻理解。 一、为什么开始关注医工交叉？ 亓教授坦言，自己对医工交叉的兴趣源自三个主要原因。 第一，看到许多大专家们已经在尝试这个领域。 "最早，我接触临床时 ...